SCHEMBL30833112

SCHEMBL30833112

CC(C)(C)OC(=O)N1CCN(c2cc(F)cnc2C2(F)CCOCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.42
USP2 O75604 1/20 0.42
GPR119 Q8TDV5 5/20 0.42
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
RECQL P46063 1/20 0.39
PIK3R1 P27986 2/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833113 0.92 PIK3CA (0.49) PIK3CASMN1; SMN2USP2GPR119CKS1B
SCHEMBL29335913 0.78 GPR119 (0.41) GPR119
SCHEMBL31046508 0.78 GPR119 (0.41) GPR119
SCHEMBL31378528 0.78 GPR119 (0.49) SMN1; SMN2GPR119CKS1BSKP1SKP2
SCHEMBL30833118 0.77 GPR119 (0.48) SMN1; SMN2GPR119CKS1BSKP1SKP2
SCHEMBL26113732 0.77 POLB (0.49) SMN1; SMN2GPR119CKS1BSKP1SKP2
SCHEMBL31651742 0.76 GPR119 (0.47) SMN1; SMN2GPR119CKS1BSKP1SKP2
SCHEMBL24989545 0.74 GPR119 (0.47) GPR119CKS1BSKP1SKP2SMARCA2
SCHEMBL31046207 0.74 GPR119 (0.41) GPR119
SCHEMBL29335912 0.74 GPR119 (0.41) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587432-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF Cerevel Therapeutics, LLC (US) 2025-07-23 EP disclosed
WO-2024059249-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS, LLC (US) 2024-03-21 WO disclosed